سعر سبازموكيور 60مجم 30 قرص 2024

Drotaverine 60 mg tablets, 30 tablets, Alfacure Pharmaceuticals (Egypt); smooth-muscle antispasmodic.

• Drotaverine: smooth-muscle spasm associated with biliary and urinary tract disorders; adjunctively gastrointestinal smooth-muscle spasm and dysmenorrhoea.Population: AdultsNational Agency for Medicines and Medical Devices of Romania (ANMDMR)

• Rare: allergic reactions (angioedema, urticaria, rash, pruritus), palpitations, hypotension, headache, vertigo, insomnia, nausea, constipation; anaphylactic shock (potentially fatal) has been reported with the injectable form; injection-site reactions.General active-ingredient information · National Agency for Medicines and Medical Devices of Romania (ANMDMR)

• Hypersensitivity to drotaverine or any excipient; severe hepatic impairment; severe renal impairment; severe heart failure (low-output syndrome).General active-ingredient information · National Agency for Medicines and Medical Devices of Romania (ANMDMR)

• Use with caution in patients with hypotension. Intravenous administration should be given only with the patient lying down because of the risk of collapse.General active-ingredient information · National Agency for Medicines and Medical Devices of Romania (ANMDMR)

• LevodopaPapaverine-type phosphodiesterase inhibitors reduce the antiparkinsonian effect of levodopa; rigidity and tremor may worsen when drotaverine is given with levodopa.National Agency for Medicines and Medical Devices of Romania (ANMDMR)

• Limited data in pregnant women; animal studies showed no direct or indirect harmful effects on pregnancy or embryo-fetal development, but caution is required when prescribing in pregnancy.General active-ingredient information · National Agency for Medicines and Medical Devices of Romania (ANMDMR)
• Excretion in breast milk has not been studied; use during breastfeeding is not recommended.General active-ingredient information · National Agency for Medicines and Medical Devices of Romania (ANMDMR)

• Drotaverine: Inhibits phosphodiesterase IV, raising cAMP and inactivating myosin light-chain kinase, which relaxes smooth muscle of the gastrointestinal, biliary, urogenital and vascular systems; it does not inhibit PDE III, so it has no major cardiovascular effects (Romanian SmPC).